Personalised treatment for Alzheimer’s disease investigated
12 December 2008Tweet
UK research institutes will use InforSense's translational research tools in Alzheimer's disease studies to advance the development of early diagnostic tools and develop personalised medicine treatments within mental health research.
For the first time, informaticians, researchers and clinicians will be able to directly access their entire patient and 'omics' data through a common data analysis platform. The InforSense solution will eliminate errors associated with manual data processes and bottlenecks relating to data access and analysis bynon-specialist end users.
The National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health at the South London and Maudsley National Health Service (NHS) Foundation Trust (SLaM) and Institute of Psychiatry, King's College London will use the tools.
'Our research centres on understanding the molecular and cellular events that take place in the brain in Alzheimer's disease and in particular we are working on blood-based biomarkers to aid early diagnosis,' said Simon Lovestone, professor of Old Age Psychiatry at King's College London and director of the Biomedical Research Centre for Mental Health. 'The translational tools that InforSense provides will enable us to have an integrated data set under a common system that informaticians, researchers and clinicians can all use to access and analyse data. This will result in improved data sharing and removal of access bottlenecks, speeding up the speed and accuracy of novel biomarker identification.'
Translational research is the practice of linking clinical and research data to identify early diagnostics, also known as biomarkers, improve disease understanding and ultimately enhance patient care. The InforSense Translational Research solution, including the InforSense platform, ClinicalSense, GenSense, and BioSense, will be used by the Biomedical Research Centre for Mental Health to integrate and analyse patient, genotyping, transcriptomics, proteomics and MRI data to support the identification of biomarkers. Researchers will also be able to access and analyse data using the VisualSense interactive web portal.